Medtronic Aims To Double Its Presence In Emerging Markets By 2015-2016
This article was originally published in PharmAsia News
In its first in-depth investor meeting in two years, Medtronic emphasized emerging markets, its ability to demonstrate economic worth, broad product offerings and pipeline as keys to growth.
You may also be interested in...
HeartWare ventricular assist device gains expanded labeling in Europe. Medigus gets 510(k) clearance for endoscopic GERD treatment. More new products.
Recently inked partnerships with Aetna and a regional Italian government are focused on improving the economic data that Medtronic has at its disposal in support of its devices.
New data on cardiac, diabetes and cancer testing.